Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07231588 · ClinicalTrials.gov registry record · Early Phase 1
Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation
A Early Phase 1 study of Radiation Injuries, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07231588: Recruiting Early Phase 1 study of Radiation Injuries, sponsored by University of Cincinnati.
NCT07231588 is a Early Phase 1 study of Radiation Injuries that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 20 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07231588, a Early Phase 1 study of Radiation Injuries, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is to determine if an oral probiotic, Pendulum Glucose Control (PGC), can be safely given to patients during pelvic radiation therapy (RT). The researchers will study if the probiotics lessen gastrointestinal toxicity during pelvic radiation.
Primary Outcome
1\. To evaluate Pendulum Glucose Control (PGC) Probiotic Adherence Rate (PAR). a. To assess Probiotic Adherence Rate (PAR), pill counts will be conducted at week 6 and week 10.
Conditions Studied
Interventions
- BIOLOGICAL Pendulum Glucose Control (PGC)
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-29 |
| Est. Completion | 2026-12-29 |
| Phase | Early Phase 1 |
What NCT07231588 shows while recruiting
NCT07231588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Radiation Injuries appearing as the primary indexed condition, and to 1 intervention - of which Pendulum Glucose Control (PGC) is the first listed.
NCT07231588 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07231588 about?
NCT07231588 is a clinical study titled "Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation". This research is to determine if an oral probiotic, Pendulum Glucose Control (PGC), can be safely given to patients during pelvic radiation therapy (RT). The researchers will study if the probiotics lessen gastrointestinal toxicity during pelvic radiation.
What is the current status of trial NCT07231588?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-01-29. Estimated completion is 2026-12-29.
What conditions does trial NCT07231588 study?
This clinical trial studies the following conditions: Radiation Injuries.
What interventions are being tested in trial NCT07231588?
The interventions under investigation include: Pendulum Glucose Control (PGC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07231588?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07231588 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07231588's enrollment target sits among peer trials
20 1157th of 2000 higher than 710 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI